Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors
GlobeNewswire
--Eisbach Is Enabling the Potential of Synthetic Lethality by Developing Novel Compounds to Exploit Molecular Vulnerabilities..